Exalys Therapeutics
San Diego
About Exalys Therapeutics
Exalys Therapeutics is developing a portfolio of novel anti-inflammatory therapeutics with best-in-class properties to target a range of diseases with urgent unmet needs and limited treatment options. Exalys is initially targeting postoperative delirium, the most common complication of surgery in older patients and a key driver of poor health outcomes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2020)
- Website: exalystx.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Canonical: https://fsome.com/organization/exalys-therapeutics-149146 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.